廣濟藥業(000952.SZ):擬與武漢同泰啟新企業管理諮詢合夥企業共同出資3000萬元成立合資公司
格隆匯12月7日丨廣濟藥業(000952.SZ)公佈,為實現公司“原料藥+製劑”兩輪驅動的發展戰略,在銷售和研發兩端發力,形成研發、生產、銷售的良性循環。公司擬以“混改”方式引進研發團隊,加強公司研發能力建設,擬與武漢同泰啟新企業管理諮詢合夥企業(有限合夥)(研發人員持股平台)共同以現金出資人民幣3000萬元成立合資公司湖北廣濟醫藥科技有限公司(暫定,最終以工商登記機關核准登記為準),其中:公司出資人民幣2700萬元,佔該合資公司90%股權;武漢同泰啟新企業管理諮詢合夥企業(有限合夥)出資人民幣300萬元,佔該合資公司10%股權。
擬設立的合資公司經營範圍:藥品、生物製品、保健食品、診斷試劑、診療技術、醫療器械、實驗室設備的技術開發、技術諮詢(不含診療)、技術轉讓;對企業及生物醫藥項目的孵化;實驗室設備及試劑(不含危險品)的銷售;市場營銷策劃;貨物進出口、技術進出口(不含國家禁止或限制進出口的貨物或技術)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.